UPDATE: Treating COVID-19 in PD and other Movement Disorders: A Review of Drug Interactions

MDS OnDemand Series

 

Available starting August 28, 2020

This accredited webinar is provided free of cost to all members and non-members.
 

Register

Presented by

Mónica M. Kurtis, MD and Pablo Mir, MD, PhD

Course Description

This is an update to the webinar published on June 5, 2020.

As the number of people infected by SARS-CoV-2 continues to rise, it is our responsibility to learn how this universal health crisis can impact Movement Disorder patients’ care. There are a number of experimental treatments being used to treat COVID-19, based on repurposed drugs and more recent antivirals and inmunomodulators. The mechanisms of action and side effects of these drugs vary widely and may interact with treatments of some neurological disorders, such as Parkinson’s disease and other movement disorders. To date, there is no data suggesting that PD, or any other movement disorder, increases the risk of developing COVID-19. However, movement disorder patients may have an increased risk of infection if living in nursing homes and may develop severe disease due to advanced age or comorbid diseases (i.e. hypertension or diabetes).

This course will discuss possible pharmacological interactions between experimental COVID-19 drugs and the established treatments used in PD, tremor, dystonia, chorea and tics. Further, this course will provide guidelines to Movement Disorders specialists as well as general neurologists to ensure that their patients with COVID-19 are treated safely. Necessary drug adjustments will be discussed for each movement disorder drug and also for drugs that are commonly used to treat non motor symptoms in movement disorder patients such as GI problems, psychiatric comorbidities, dementia, and insomnia. Finally, some clinical cases will be put forth to discuss potential problems and possible solutions.

Target Audience

Movement Disorders specialists, Movement Disorders fellows, general neurologists, neurology residents, and general practitioners.

Learning Objectives
  1. Identify possible interactions between COVID-19 drugs and PD medication
  2. Adjust dopaminergic therapy in PD patients with COVID-19
  3. Provide safe and accurate information to patients and other physician during the COVID-19 pandemic
Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Parkinson and Movement Disorder Society is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The International Parkinson and Movement Disorder Society designates this activity for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation.

Satisfactory Completion

Participants must complete an evaluation for each session they attend to receive continuing medical education credit. Your chosen session(s) must be attended in their entirety. Partial credit for individual sessions is not available.

Content Validity Statement

All recommendations involving clinical medicine in MDS activities are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the case of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendations conforms to the generally accepted standards of experimental design, data collection and analysis. Activities that promote recommendations, treatment or manners of practicing medicine not within the definition of CME or are knowing to have risks or dangers that outweigh the benefits or are knowing to be ineffective in the treatment of patients do not constitute valid CME.

Faculty Financial Disclosure Information

All individuals in control of content for this webinar are required to disclose all relevant financial relationships with commercial interests as defined by the ACCME. Disclosure information is available here.

Top

We use cookies to give you the best possible experience with our website. These cookies are also used to ensure we show you content that is relevant to you. If you continue without changing your settings, you are agreeing to our use of cookies to improve your user experience. You can click the cookie settings link on our website to change your cookie settings at any time. Note: The MDS site uses related multiple domains, including mds.movementdisorders.org and mds.execinc.com. This cookie policy only covers the primary movementdisorders.org and mdscongress.org domain. Please refer to the MDS Privacy Policy for information on how to configure cookies for all other domains on the MDS site.
Cookie PolicyPrivacy Notice